Avadel, Lumryz
Avadel Gets Expanded FDA OK of Lumryz for Use in Children
Avadel Pharmaceuticals has won expanded Food and Drug Administration approval of its narcolepsy drug Lumryz for use in children. Avadel on Thursday said the FDA nod covers Lumryz for the treatment of cataplexy, or excessive daytime sleepiness, in children ages seven and older with narcolepsy, a chronic sleep disorder.
Lumryz is an extended-release formulation of sodium oxybate, a central nervous system (CNS) depressant. Its therapeutic effects are believed to be mediated through GABA B actions at noradrenergic and ...
Surgeons at a Kentucky hospital were preparing to remove the organs from a donor who had been declared dead only to realize ...
The U.S. Food and Drug Administration has approved Avadel Pharmaceuticals' sleep disorder drug for children aged 7 years and ...
Avadel's drug contains a central nervous system depressant drug called sodium oxybate, which helps increase the amount of ...
Ardent value investor Seth Klarman is swapping out shares of search engine juggernaut Alphabet for a relatively unknown ...
Shares of Jazz Pharmaceuticals are trading only slightly higher in the last few weeks despite two unexpected wins. Explore ...
A summary of recent health news updates reveals declining Marburg cases in Rwanda, Texas suing a doctor over prescribing ...
(RTTNews) - Avadel Pharmaceuticals plc (AVDL), Tuesday revealed that 94 percent of patients in RESTORE study with narcolepsy preferred the once-nightly regimen of Lumryz over twice-nightly Oxybate ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback